The recent volatility surrounding Radius Health shares should lessen as the market starts focusing on its osteoporosis drug Abaloparatide, said the company's CEO Robert Ward. Radius Health sold 6.5 million shares of stock $8 a share in a June IPO, raising $52 million. Abaloparatide is in Phase III development and has exhibited faster improvement in bone mineral density at all sites in a pair of confirmatory Phase II studies. Ward said he expects the pivotal trial readout in December and hopes to submit and NDA in mid-2015. Ward said the company has not partnered with a larger drug company yet, and has raised more than enough money to get Abaloparatide to market.

If you liked this article you might like

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Biotech Movers: BioCryst, Omeros, Radius Health

Insiders Love Bioverativ, Juno Therapeutics and More

One of the World's Largest Private Equity Firms Has Seen Its Stock Soar - Now What?

Jim Cramer: Radius Health Is a Takeover Target